Numelvi 7.2mg Tablet for Dogs

Effective Relief for Canine Allergic Skin Conditions

When your dog suffers from persistent itching due to allergic dermatitis or atopic dermatitis, it can significantly impact their comfort and well-being. Numelvi 7.2mg Tablet for Dogs, with its active substance Atinvicitinib, provides targeted relief by addressing the underlying causes of this discomfort, allowing your dog to feel more at ease.

How Atinvicitinib Works

Atinvicitinib is a selective Janus kinase (JAK) inhibitor, which means it specifically targets the JAK1 enzyme. This enzyme plays a crucial role in the pathways that lead to inflammation and pruritus (itching) in dogs. By inhibiting JAK1, Atinvicitinib helps to:

• Reduce the inflammatory response in the skin.
• Lessen the sensation of itching, providing relief.
• Allow your dog to recover and enjoy daily activities without constant scratching.

This targeted action helps manage the clinical manifestations of these skin conditions, offering your pet much-needed comfort.

Why Choose Weldricks Pharmacy for Your Pet's Prescription?

At Weldricks Pharmacy, we understand that your pet's health is a top priority. As a trusted, UK-regulated pharmacy family-run for nearly 100 years, we are dedicated to providing accessible and professional healthcare solutions for your beloved animals. When you choose us for your Numelvi 7.2mg Tablet for Dogs, you benefit from:

• Convenient Online Service: Easily order your vet prescriptions from the comfort of your home.
• Discreet Packaging: Your order arrives in plain boxes without indicating the contents.
• Fast & Reliable Delivery: Enjoy free UK delivery on orders over £40, with options for next-day delivery.
• Trusted Quality: Our commitment to excellent service is reflected in our 4.9/5 rating on Trustpilot and Reviews.io from over 85,000 reviews.

We are here to support you in managing your dog's health needs confidently and affordably.

It is critical to administer Numelvi 7.2mg Tablet for Dogs exactly as prescribed by your veterinary surgeon. Always follow your vet's specific dosage instructions based on your dog's weight and condition.

For general guidance, this veterinary medicinal product should be administered once daily at the recommended dose of 0.8 to 1.2 mg atinvicitinib/kg bodyweight. The tablets should be given at or around the time of feeding. The tablets are breakable along the score line and can be divided into two equal halves to allow for precise dosing.

The duration of treatment will be determined by your veterinarian based on an individual benefit-risk assessment for your dog.

Contraindications

• Do not use Numelvi 7.2mg Tablet for Dogs in cases of hypersensitivity to the active substance (Atinvicitinib) or any of the excipients.

Special Precautions for Use in Target Species (Dogs)

• The safety of this veterinary medicinal product has not been investigated in dogs younger than 6 months of age or weighing less than 3 kg. Use in such animals should be based on a thorough benefit-risk assessment by a responsible veterinarian.
• Complicating factors, such as bacterial, fungal, or parasitic infections (e.g., fleas, Demodex mites), as well as any underlying causes of allergic and atopic dermatitis (e.g., flea allergy, contact allergy, food allergy), should be investigated and treated concurrently.
• The use of Numelvi 7.2mg Tablet for Dogs has not been evaluated in combination with systemic immunosuppressive agents like glucocorticoids or cyclosporine.
• Safety has not been investigated in dogs with evidence of immunosuppression (for example, uncontrolled primary hypothyroidism, rickettsial disease) or dogs with evidence of progressive malignant neoplasia. Use in these cases should be based on a benefit-risk assessment by a responsible veterinarian.

Use During Pregnancy, Lactation, or in Breeding Animals

• The safety of this veterinary medicinal product has not been established during pregnancy and lactation or in breeding dogs.
• The use of Numelvi 7.2mg Tablet for Dogs is not recommended during pregnancy and lactation. Laboratory studies in rats and rabbits have shown effects on prenatal development related to the class of JAK inhibitors.
• The use of this product is not recommended in breeding animals, as laboratory studies in male rats showed an effect on sperm counts and motility.

Common Adverse Events (Side Effects)

In dogs, the following adverse events were observed in 1 to 10 animals out of 100 treated:

• Emesis (vomiting)
• Diarrhoea
• Lethargy
• Anorexia (loss of appetite)

It is important to report any adverse events to your veterinarian or the national competent authority to ensure ongoing safety monitoring of veterinary medicinal products.

Symptoms of Overdose

While Atinvicitinib has shown high selectivity for JAK1, reducing the potential for adverse effects, significant overdoses may lead to a higher susceptibility to infection, such as bacterial, fungal, and/or parasitic skin disease. In the event of adverse clinical effects following an overdose, the dog should be treated symptomatically.

Special Precautions for the Person Administering the Product

• Wash hands thoroughly with soap and water immediately after administering the veterinary medicinal product.

Disposal of Unused Veterinary Medicinal Products or Waste Materials

• Medicines should not be disposed of via wastewater.
• Utilise take-back schemes for the disposal of any unused veterinary medicinal product or waste materials in accordance with local requirements and national collection systems.

Active Substance

• Atinvicitinib 7.2 mg

Excipients

• Cellulose, microcrystalline
• Lactose monohydrate
• Sodium starch glycolate (type A)
• Tocofersolan
• Hydroxypropylcellulose
• Silica, colloidal anhydrous
• Magnesium stearate